Марказий Осиё эндокринологик журнали Ҷилди 4 № 3 (2024)
What is Known About the Type 1 Sodium-glucose Co-transporter?
Рахимова Гульнара Нишановна, Иброхимов Худойберди Хусанжон угли
Аннотатсия
From numerous studies, it is known about the role of SGLT-2 inhibitors in reducing glycemia, cardio- and nephroprotection in patients with type 2 diabetes. SGLT-type 1 has been studied somewhat less, the management and activity of which may also be the key to compensating for type 2 diabetes, chronic diseases of the heart, kidneys and other organs and tissues. At the moment, inhibition of SGLT-1 in humans can only be achieved by using combined inhibitors of SGLT-1 /SGLT-2. Drugs with selective inhibition of SGLT-1 are actively studied in animals and in vitro studies. This review is devoted to the principles of the action of sodium-glucose cotransporter type 1, the effect of inhibition of SGLT-1 on pathological conditions, and also evaluated the prospects for the use of iSGLT-1 in humans.
: ингибиторы натрий-глюкозного транспортера 1 типаингибиторы натрий глюкозного ко-транспортера 2 типасахарный диабет 2 типаканаглифлозинсотаглифлозинмизаглифлозинtype 1 sodium-glucose transporter inhibitorstype 2 sodium glucose transporter inhibitorstype 2 diabetes mellituscanagliflozin
Манбаи метамаълумот: бойгонии OAI-PMH-и маҷалла · Sindex матни пурраро нигоҳ намедорад, ба манбаъ пайванд медиҳад.